Supplementary Table 1: Selection of candidate genes in single nucleotide polymorphisms in
gemcitabine pathway
Gemcitabine
Genes
pathway
Transporters
Selected candidate
Investigated SNPs
genes
SLC29A1, SLC29A2,
SLC29A1 [1-3]
SLC28A1, SLC28A2,
SLC28A3, ABCB1,
[4-6]
ABCC5 [7]
ABCC5
Metabolic
DCK, DCTD, CMPK1,
enzymes
NME1, 5’-NT, CDA
None: intronic SNPs
None: non-functional
SNPs [8]
DCK [9, 10]
rs2306744,
rs67437265,
rs4643786
CDTD [11]
None: MAF<1% [11]
5’-NT [12]
None: MAF<1% [12]
CDA [13, 14]
rs3215400,
rs2072671,
rs60369023
Targets
RRM1, RRM2, POLE,
POL2A, TYMS
RRM1 [15, 16]
rs1662163,
rs11030918,
rs12806698,
rs183484, rs1042927
SNP, single nucleotide polymrophism
REFERENCES
1.
Garcia-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M.
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003; 9: 5000-5008.
2.
Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W et al.
Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential
solutions. Scand J Gastroenterol 2009; 44: 782-786.
3.
Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression
of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun
2001; 280: 951-959.
4.
Gusella M, Pasini F, Bolzonella C, Meneghetti S, Barile C, Bononi A et al.
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict
gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol 2011; 71:
437-444.
5.
Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE. Functional single
nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1.
Pharmacogenet Genomics 2006; 16: 315-320.
6.
Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D. Single nucleotide
polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug
toxicity. Clin Cancer Res 2009; 16: 320-329.
7.
Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and
transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with
locally advanced pancreatic cancer. Cancer 2010; 116: 5325-5335.
8.
Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Bohm M et al.
Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular
export pump for cyclic nucleotides, in human heart. Am J Pathol 2003; 163: 1567-1577.
9.
Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V et al.
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel
genetic variants. J Pharmacol Exp Ther 2007; 323: 935-945.
10.
Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G et al. Association between single
nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute
myeloid leukaemia patients. Pharmacogenetics 2004; 14: 759-768.
11.
Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED et al.
Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene
resequencing and functional genomics. Clin Cancer Res 2006; 12: 1794-1803.
12.
Aksoy P, Zhu MJ, Kalari KR, Moon I, Pelleymounter LL, Eckloff BW et al. Cytosolic
5'-nucleotidase
III
(NT5C3):
gene
sequence
variation
and
functional
genomics.
Pharmacogenet Genomics 2009; 19: 567-576.
13.
Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S et al. Homozygous
CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer
patients. Br J Cancer 2009; 100: 870-873.
14.
Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al.
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine
deaminase polymorphism. J Clin Oncol 2007; 25: 32-42.
15.
Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A et al. Ribonucleotide
reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical
relevance. Lung Cancer 2005; 47: 183-192.
16.
Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS et al. Efficacy of gemcitabine
in patients with non-small cell lung cancer according to promoter polymorphisms of the
ribonucleotide reductase M1 gene. Clin Cancer Res 2008; 14: 3083-3088.